Assertio (NASDAQ:ASRT) Issues Quarterly Earnings Results

Assertio (NASDAQ:ASRT) posted its earnings results on Monday, March 16th. The company reported ($1.86) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.05) by $1.19, Zacks reports. Assertio had a negative return on equity of 30.26% and a negative net margin of 25.59%.The firm had revenue of $13.54 million during the quarter, compared to analysts’ expectations of $6.20 million.

Here are the key takeaways from Assertio’s conference call:

• Rolvedon integration complete — the product has been relabeled under Assertio, regular sales are expected to resume in Q2 2026, and management views Rolvedon as a long-term growth asset with IP protection through 2039 and upside to >$100M in annual sales potential.
• 2026 financial outlook — the company initiated guidance of $110M–$125M revenue and $28M–$40M adjusted EBITDA, driven by accretive Rolvedon growth and structural cost savings (lower litigation, Otrexup decommercialization, and Q4 restructuring).
• Quarterly results and cash impact — Q4 product sales fell to $12.8M (from $29.6M) due to channel timing from the Rolvedon sell‑in, and cash dropped to $63.4M as working capital expanded; management expects working capital variability through Q1 with normalization by end of April.
• Strategic shift and BD discipline — Assertio will move away from buying on‑market specialty assets at current prices, focusing selectively on oncology therapeutics (on‑market or late‑stage) that leverage its community oncology commercial platform.
• Tail asset dynamics — Indocin faces expected ongoing generic erosion (one more generic anticipated in 2026) and Sympazan’s returns have been lower than expected, leading management to limit further investment in that asset.

Assertio Stock Down 0.7%

Assertio stock opened at $18.02 on Wednesday. The company has a current ratio of 1.70, a quick ratio of 1.51 and a debt-to-equity ratio of 0.42. Assertio has a 1-year low of $8.55 and a 1-year high of $20.45. The company has a fifty day simple moving average of $14.81 and a 200 day simple moving average of $12.61. The company has a market cap of $116.23 million, a P/E ratio of -3.71 and a beta of 0.43.

Hedge Funds Weigh In On Assertio

A number of large investors have recently modified their holdings of the business. Virtu Financial LLC bought a new position in shares of Assertio in the 3rd quarter valued at about $26,000. Rothschild Wealth LLC acquired a new stake in shares of Assertio in the fourth quarter valued at about $172,000. Perritt Capital Management Inc raised its holdings in Assertio by 51.6% during the third quarter. Perritt Capital Management Inc now owns 350,316 shares of the company’s stock worth $309,000 after acquiring an additional 119,281 shares in the last quarter. Edgewood Management LLC bought a new stake in Assertio during the fourth quarter worth about $975,000. Finally, Opaleye Management Inc. acquired a new position in Assertio during the fourth quarter valued at approximately $2,585,000. 48.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. HC Wainwright reissued a “neutral” rating and set a $18.00 target price (down from $35.00) on shares of Assertio in a research note on Thursday, April 9th. Maxim Group lowered shares of Assertio from a “strong-buy” rating to a “hold” rating in a research note on Thursday, April 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assertio in a report on Monday. Zacks Research cut shares of Assertio from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. Finally, Wall Street Zen downgraded shares of Assertio from a “buy” rating to a “hold” rating in a research report on Saturday, March 21st. One research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $18.00.

Assertio Company Profile

Assertio Therapeutics, Inc, formerly known as Depomed, is a specialty pharmaceutical company focused on the development and commercialization of therapies for central nervous system (CNS) disorders, including neuropathic pain, migraine and breakthrough cancer pain. The company’s commercial portfolio includes three FDA-approved products—Qutenza (8% capsaicin) for postherpetic neuralgia, Butrans (buprenorphine) transdermal system for chronic pain and Onsolis (fentanyl buccal soluble film) for breakthrough cancer pain—which are marketed primarily in the United States under licensing agreements with global partners.

In addition to its marketed therapies, Assertio maintains a pipeline of preclinical and clinical-stage candidates targeting a range of pain and neurological conditions.